Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan

Intervirology

Volumn 49, Issue 1-2, 2006, Pages 76-81

  Lee, Chuan Mo ^a   Hung, Chao Hung ^a   Lu, Sheng Nan ^a   Wang, Jing Houng ^a   Tung, Hung Da ^a   Huang, Wu Shiung ^a   Chen, Chao Long ^a   Chen, Wei Jen ^a   Changchien, Chi Sin ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Genotypes; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HOST FACTOR 1; INITIATION FACTOR 2ALPHA; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS ANTIBODY;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TAIWAN; VIREMIA; VIRUS INFECTION;

AGE FACTORS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; MUTATION; RIBAVIRIN; RNA, VIRAL; SPECIES SPECIFICITY; TAIWAN; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS; VIREMIA;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 24944583152     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087267     Document Type: Conference Paper

References (61)

1. Beasley RP: Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: Epidemiological consideration. Hepatology 1982;2:S21-S26.
2. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, Houghton M, Choo QL, Kuo G: Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-591.
3. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ: Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-1213.
4. Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ: Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;86:1143-1150.
5. Dazza MC, Meneses LV, Girard PM, Astagneau P, Villaroel C, Delaporte E, Larouze B: Absence of a relationship between antibodies to hepatitis C virus and hepatocellular carcinoma in Mozambique. Am J Trop Med Hyg 1993;48:237-242.
6. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, Castillo R, Rodes J: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;ii:1004-1006.
7. Kiyosawa K, Tanaka E, Sodeyama T, Yoshizawa K, Yabu K, Furuta K, Imai H, Nakano Y, Usuda S, Uemura K, Furuta S, Watanabe Y, Watanabe J, Fukuda Y, Takayama T: Transmission of hepatitis C in an isolated area in Japan: Community-acquired infection. Gastroenterology 1994;106:1596-1602.
8. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, Esmat G, Thomas DL, Strickland GT: High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994;51:563-567.
9. Louis FJ, Maubert B, Le Hesran JY, Kemmegne J, Delaporte E, Louis JP: High prevalence of anti-hepatitis C virus antibodies in a Cameroon rural forest area. Trans R Soc Trop Med Hyg 1994;88:53-54.
10. Tong MJ, Sun SC, Schaeffer BT, Chang NK, Lo KJ, Peters RL: Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med 1971;75:687-691.
11. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, Hahn, LC, Choo QL, Wang TH, Houghton M: Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: The Taiwan experience. J Infect Dis 1990;162:817-822.
12. Sheu JC, Wang JT, Wang TH, Wang CY, Yang PM, Huang GT, Shih LN, Lee HS, Chen DS: Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993;17:192-198.
13. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, Wang JH, Peng CF, Shih CH, You SL, Lu CF, Chen CJ, Chang WY: Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547-550.
14. Wang JH, Lu SN, Wu JC, Huang JF, Yu ML, Chen SC, Chuang WL: A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. Trans R Soc Trop Med Hyg 1999;93:253-254.
15. Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ: The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992;69:342-345.
16. Liaw YF, Chien RN, Sheen IS, Lin DY, Lin HH, Chu CM: Hepatitis C virus infection in patients with chronic liver diseases in an endemic area for hepatitis B virus infection. Gastroenterol Jpn 1991;26:S167-S169.
17. Lu SN, Lee CM, Changchien CS, Chen CJ: Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan). Trans R Soc Trop Med Hyg 1999;93:600-602.
18. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-1859.
19. Chang SJ, Chen HC, Ying J, Lu CF, Ko YC: Risk factors of hepatitis C virus infection in a Taiwanese aboriginal community. Kaohsiung J Med Sci 1996;12:241-247.
20. Lu SN, Chue PY, Chen IL, Wang JH, Huang JF, Peng CF, Shih CH, Chang WY: Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan. Kaohsiung J Med Sci 1997;13:605-608.
21. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
22. Zignego AL, De Carli M, Monti M, Careccia G, La Villa G, Giannini C, D'Elios MM, Del Prete G, Gentilini P: Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 1995;47:58-64.
23. Simmonds P: Clinical relevance of hepatitis C virus genotypes. Gut 1997;40:291-293.
24. Agha S, Tanaka Y, Saudy N, Kurbanov F, Abo-Zeid M, El-Malky M, Khalaf M, Ohta N, Yoshizawa H, Mizokami M: Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: A collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol 2004;73:216-222.
25. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R, Lin C, Lai C, Leong S, Medgyesi GA, Hejjas M, Kiyokawa H, Fukada K, Cuypers T, Saeed AA, Al-Rasheed AM, Lin M, Simmonds P: Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol 1994;32:884-892.
26. Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, Mishiro S: Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-2390.
27. Wu JS, Lee HF, Hsiau HL, Lu HY, Chou WH, Lu CF, Chen HY, Lee FN, Chen PY, Tam KM: Genotype distribution of hepatitis C virus infection in Taiwan. J Med Virol 1994;44:74-79.
28. Chan CY, Lee SD, Hwang SJ, Lu RH, Lu CL, Lo KJ: Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C. J Infect Dis 1995;171:443-446.
29. Chen CH, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, Lee CZ, Chen DS: Genotypes of hepatitis C virus in chronic liver disease in Taiwan. J Med Virol 1994;44:234-236.
30. Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, Lu SN, Huang JF, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY: Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001;65:58-65.
31. Ikeda K, Kobayashi M, Someya T, Saitoh S, Tsubota A, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H: Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: A multivariate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology 2002;45:71-78.
32. Reid AE, Koziel MJ, Aiza I, Jeffers L, Reddy R, Schiff E, Lau JY, Dienstag JL, Liang TJ: Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Am J Gastroenterol 1999;94:1619-1626.
33. Yotsuyanagi H, Koike K, Yasuda K, Moriya K, Hino K, Kurokawa K, Iino S: Hepatitis C virus genotypes and development of hepatocellular carcinoma. Cancer 1995;76:1352-1355.
34. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
35. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
36. Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, Shingai Y, Konishi T, Yamashita S, Uchida K, Mori K, Hanada H, Kodama T, Nukui K, Okita K: Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2002;9:370-376.
37. Omata M, Yoshida H: Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol 2003;237:S47-S51.
38. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
39. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
40. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
41. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
42. Lin R, Liddle C, Byth K, Farrell GC: Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 1996;3:85-96.
43. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen TM, Chen CH, Changchien CS: Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol 2002;17:1307-1311.
44. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M: Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113:558-566.
45. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH: Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996;125:634-639.
46. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG: Control of PKR protein kinase by hepatitis C virus nonstructural 5 A protein: Molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18:5208-5218.
47. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-110.
48. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
49. Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, Capron D, Capron JP, Lunel F, Stuyver L, Duverlie G: Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997;27:72-77.
50. Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, Loiacono O, Siciliano R, Levrero M, Raimondo G: Long-term response to interferon alpha is unrelated to 'interferon sensitivity determining region' variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 1999;30:1023-1027.
51. Chung RT, Monto A, Dienstag JL, Kaplan LM: Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol 1999;58:353-358.
52. Cavalletto L, Chemello L, Donada C, Casarin P, Belussi F, Bernardinello E, Marino F, Pontisso P, Gatta A, Alberti A: The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. J Hepatol 2000;33:128-134.
53. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, Chen TM, Hu TH, Chen WJ, Changchien CS: Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003;10:87-94.
54. Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, Zeuzem S: Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 1999;30:1004-1013.
55. Macquillan GC, Niu X, Speers D, English S, Garas G, Harnett GB, Reed WD, Allan JE, Jeffrey GP: Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population? J Gastroenterol Hepatol 2004;19:551-557.
56. Cappiello G, Abbate I, Lo Iacono O, Longo R, Solmone M, Ferraro D, Antonucci G, Di Marco V, Di Stefano R, Craxi A, Ippolito G, Capobianchi MR: ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin. Antivir Ther 2003;8:105-110.
57. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH: Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int 2003;23:426-433.
58. Huang WS, Lu SN, Wang JH, Lee CM, Tung HD, Chen TM, Changchien CS: Prediction of viremia for cases of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Hepatogastroenterology, in press.
59. Craxi A, Camma C, Giunta M: Definition of response to antiviral therapy in chronic hepatitis C. J Hepatol 1999;31:S160-S167.
60. Pawlotsky JM: Diagnostic tests for hepatitis C. J Hepatol 1999;31:S71-S79.
61. Tung HD, Lu SN, Lee CM, Wang JH, Chen TM, Hung CH, Huang WS, Changchien CS: Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J Viral Hepat 2002;9:304-308.